meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HER2-positive
es-BC - HER2 negative - (neo)adjuvant (NA)
1
es-BC - HER2 positive - (neo)adjuvant (NA)
4
la/mBC - HER2 positive
la/mBC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive - 1st Line (L1)
5
la/mBC - HER2 positive - 2nd Line (L2)
13
HER inhibitor
HER2 inhibitor
pertuzumab based treatment
pertuzumab plus trastuzumab
pertuzumab plus trastuzumab plus docetaxel
trastuzumab based treatment
trastuzumab plus endocrine therapy
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab plus trastuzumab plus docetaxel
versus all
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs trastuzumab
vs trastuzumab plus chemotherapy
vs trastuzumab plus docetaxel
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
Statistically conclusive or suggested result
Inconclusive results
Uncertain results
Safety results
la/mBC - HER2 positive - 1st Line (L1)
breast cancer - HER2-positive
la/mBC - HER2 positive
la/mBC - HER2 positive - 1st Line (L1)
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open